Introduction
============

Major depression or deterioration of previous mood disorders is a common adverse consequence of coronary heart disease (CHD), heart failure, and cardiac revascularization procedures.[@b1-ARYA-11-295]-[@b3-ARYA-11-295] Therefore, treatment of depression is expected to result in improvement of mood condition in these patients. Despite demonstrated effects of anti-depressive treatment in heart disease patients, the use of some antidepressants have shown to be associated with some adverse cardiac and non-cardiac events that may even lead to high mortality and morbidity as well as to lower patients' survival.[@b4-ARYA-11-295]-[@b6-ARYA-11-295] Especially focusing newer antidepressants generations shows some notable adverse events (AEs) emphasizing individualize therapy to minimize these AEs.[@b7-ARYA-11-295]

Unfortunately, in the current industrialized world, the prevalence of mood disorders has an upward trend because of economic problems, the lack of social security insurance after cardiac surgeries and also significant physical and social disabilities following disease progression. In recent published meta-analyses, the overall prevalence of major depression in coronary artery disease patients has been estimated 18.7% in women and 12.0% in men.[@b8-ARYA-11-295] In patients who suffer acute myocardial infarction (MI), the prevalence of major depression ranges from 15% to 20%.[@b9-ARYA-11-295] Those with heart failure experience higher rate of depression with a range 36%.[@b10-ARYA-11-295] Although affected heart disease patients may remain undiagnosed with regard to the presence of depression, but most of these subjects treated with a variety of antidepressants and thus appearing side effects of these drugs is expectable in undertreated patients.

In this narrative review, the authors aimed to assess the findings of published studies on beneficial and also harmful effects of different types of antidepressants used in patients with heart diseases. Finally, a new categorization for selecting antidepressants according to their cardiovascular effects was described.

Materials and Methods
=====================

Using PubMed, Web of Science, SCOPUS, Index Copernicus, CINAHL, and Cochrane Database, we identified studies designed to evaluate the effects of depression and also using antidepressants on cardiovascular outcome ([Figure 1](#f1-ARYA-11-295){ref-type="fig"}). The study criteria for inclusion in the review were: a randomized controlled trial, cohort study, retrospective case-control study, case studies, animal experimental studies, or a meta-analysis published in a peer-reviewed journal, inclusion of patients with different types of cardiovascular disorders, and comparison of the effects of different antidepressants. The search strategy was based on the search terms "antidepressant" and "cardiovascular event." The searches were performed up to December 2014. All available English abstracts and full texts were reviewed. In initial reviewing, 275 papers met our inclusion criteria. By considering the exclusion criteria of no full-text availability, review without meta-analysis, and non-English language texts, and review articles without meta-analysis, 40 studies were finally assessed systematically. Among those eligible studies ([Table 1](#t1-ARYA-11-295){ref-type="table"}), 14 were cohort or historical cohort studies, 15 were randomized clinical trial, 4 were retrospective were case-control studies, 3 were meta-analyses and 2 animal studies, and 2 case studies. According to drug groups evaluated, 5 groups of antidepressant medications were assessed including (1) selective serotonin reuptake inhibitors (SSRIs) (escitalopram, sertraline, citalopram, fluoxetine, paroxetine); (2) tricyclic antidepressants (TCAs) (amitriptyline, imipramine, dezipramine.); (3) serotonin-norepinephrine reuptake inhibitors (SNRIs) (venlafaxine, duloxetine, sibutramine); (4) serotonin antagonist and reuptake inhibitors (SARIs) (trazodone); and (5) noradrenergic and specific serotonergic antidepressants (NaSSAs) (mirtazapine). Furthermore, the considered cardiovascular outcome included cardiac or non-cardiac related death, heart rate variability, ischemic events (MI), brain stroke, and hemodynamic instability. The data were abstracted, and differences were finally resolved by consensus.

Results
=======

***First antidepressants group (SSRIs)***

Most studies on cardiovascular effects of different types of SSRIs have emphasized neutralized or even beneficial cardioprotective effects of SSRIs especially newer generations on cardiovascular system. In a clinical trial study by Thase et al.[@b11-ARYA-11-295] on 3298 depressed patients, escitalopram was used at doses between 5 and 20 mg/day for two acute (8-12 weeks) and long-term (24 weeks) phases to assess cardiovascular outcome including heart rate, blood pressure (BP), treatment-emergent AEs, and electrocardiograms (ECGs). The study showed no significant difference in BP, ECG, or cardiovascular AEs, but a slight decrease in heart rate without clinical consequences. In a similar study by Hanash et al.,[@b12-ARYA-11-295] 240 patients were randomized to escitalopram 10 mg daily or matching placebo for 1-year and finally biochemical markers, as well as ECG and echocardiography patterns were assessed between study intervention groups. They could show similar findings between intervention and placebo groups in the incidence of ventricular arrhythmia and episodes of ST-segment depression, length of QTc, and systolic and diastolic echocardiographic measures as well as 1-year AEs including death, recurrent acute coronary syndrome, or need to repeating revascularization. Regarding the effects of sertraline and citalopram as other new types of SSRIs, Santangelo et al.,[@b13-ARYA-11-295] 110 patients were treated with citalopram, 20-40 mg/day, or sertraline 50-100 mg/day leading considerable reduction in cardiovascular events in a 1-year follow-up time demonstrating cardioprotective effects of these two types of antidepressants on cardiovascular system in depressed patients. Glassman et al.[@b14-ARYA-11-295] also assessed the effects of sertraline in patients with acute MI or unstable angina. In their study, depressed patients were randomly assigned to receive sertraline in flexible dosages of 50-200 mg/d or placebo for a treatment period of 6 months indicating no inter-group differences in the left ventricular function, ventricular arrhythmias, ECG patterns, and cardiovascular major AEs. The cardiovascular effects of sertraline have been also studies in children and young adolescents. In a study by Wilens et al.[@b15-ARYA-11-295] on 107 children and 80 adolescents who suffered obsessive-compulsive disorder, cardiovascular effects of sertraline with the doses of \< or = 200 mg/day for 12 weeks were assessed showing no clinically significant cardiovascular AEs in any of the subjects enrolled in the study assessed by ECG pattern and hemodynamic indices. Only, in a study by Weeke et al.,[@b16-ARYA-11-295] increased risk for cardiac arrest was reported by administrating citalopram so that in a case-control study including 19,110 patients with the history of out-of-hospital cardiac arrest, the risk for cardiac arrest increased following use of citalopram with an odds ratio 1.29. The effects of first generations of SSRIs were assessed in the earlier studies. In a study Roose et al.[@b17-ARYA-11-295] in 1998, 27 depressed patients were participated in an open medication trial of fluoxetine, up to 60 mg/day, for 7 weeks. The authors revealed a slight reduce in heart rate, a slight increase in systolic BP, and a slight increase in ejection fraction with no effect on cardiac conduction, ventricular arrhythmia, or orthostatic BP that all changes were reported to be tolerable. In another study by Yeragani et al.,[@b18-ARYA-11-295] the administration of paroxetine was suggested to be cardio-protective especially with regard to sleeping, and awake heart period variability measures. In this regard, no adverse cardiovascular events was also reported by other authors such as Acharya et al.,[@b19-ARYA-11-295] Pequignot et al.,[@b20-ARYA-11-295] Zuidersma et al.,[@b21-ARYA-11-295] Jerrell and McIntyre,[@b22-ARYA-11-295] Grace et al.,[@b23-ARYA-11-295] Swenson et al.,[@b24-ARYA-11-295] and Taylor et al.[@b25-ARYA-11-295] ([Table 1](#t1-ARYA-11-295){ref-type="table"}) following the use of SSRIs.

***Second antidepressants group (TCAs)***

The cardiovascular effects of TCAs group of drugs have been into categories of their effects on left ventricular function and also on cardiac conduction system and ECG pattern. In a clinical trial by Roose et al.,[@b26-ARYA-11-295] the use of nortriptyline with the dose of 50-150 ng/ml for 6 weeks led to a sustained increase in heart rate and also a reduction in heart rate variability. In an animal study by Jeon et al.,[@b27-ARYA-11-295] the use of nortriptyline resulted in change of ventricular repolarization process indicated by the increase in QTc indicating the effect of nortriptyline on QT prolongation. In a study by Bar et al.,[@b28-ARYA-11-295] 26 depressed subjects were treated with nortriptyline leading a decrease of non-linear measures of heart rate variability in addition to reduced cardio-respiratory coupling in the patients. In an earlier clinical trial study by Kiev et al.,[@b29-ARYA-11-295] a treatment regimen including nortriptyline 75-150 mg/day led to adverse consequences such as a slowing of cardiac conduction. Contrarily, Thayssen et al.[@b30-ARYA-11-295] in a clinical trial including elderly depressed patients who treated with imipramine or nortriptyline could not show significant changes in cardiac conduction time measurements or arrhythmias. With regard to the effects of TCAs on left ventricular functional status, Giardina et al.[@b31-ARYA-11-295] conducted a clinical trial study on 20 non-depressed cardiac patients treated for ventricular premature depolarization. The patients were administered 1 mg/kg/day imipramine or 0.5 mg/kg/day nortriptyline and finally showed that neither drug significantly changed mean left ventricular ejection fraction or peak systolic pressure end-systolic volume indicating the safety of those two drugs even in patients with impaired systolic function. Hamer et al.[@b32-ARYA-11-295] in a cohort study could show no significant association between TCAs use and CHD events or all-cause mortality risk.

Regarding cardiovascular changes following the use of amitriptyline, amitriptyline usage is associated with significant prolongation of QRS and QTc as well as increased in heart rate while little overall change can be revealed in BP.[@b33-ARYA-11-295] Furthermore, desipramine may be led to release serum norepinephrine may results in increase the risk of exercise-associated arrhythmias.[@b34-ARYA-11-295]

***Third antidepressants group (SNRIs)***

With respect to the effects of SNRIs group on cardiovascular system, a limited number of studies have been conducted. In a recent retrospective study by Ho et al.[@b35-ARYA-11-295] by reviewing the records of 48,876 an elder patients, who receiving venlafaxine, not only low to moderate doses of this drug had no adverse cardiovascular events, but also the lower risk of heart failure in comparison with other drugs such as sertraline was also shown. Regarding the effects of another type of drug in this group, duloxetine, Xue et al.[@b36-ARYA-11-295] prospectively assessed the cardiovascular events in 17,386 depressed patients receiving duloxetine and showed no difference in the rate of AEs between depressed patients treated with duloxetine and untreated ones emphasizing occurrence of cardiovascular events by depression itself, not by duloxetine. In a meta-analysis by Wernicke et al.,[@b37-ARYA-11-295] 42 placebo-controlled clinical trials of 8504 patients who were treated with duloxetine were systematically reviewed. They showed slight bit not significant decreases from baseline in RR, QRS, and QT intervals, as well as no increased risk of sustained BP elevation with duloxetine treatment. More attentions have focused the cardiovascular consequences of using sibutramine as a drug in the SNRIs group. In a study by Scheen,[@b38-ARYA-11-295] the efficacy/safety ratio of sibutramine in overweight/obese high-risk subjects was prospectively assessed. In this cohort study, sibutramine 10 mg/day was administered for 6 weeks. Long-term follow-up of patients showed the increased risk for nonfatal MI and nonfatal stroke and thus it should not be recommended in obese subjects with previous history of cardiovascular disorders. In another cohort study by James et al.,[@b39-ARYA-11-295] 10,744 overweight or obese older subjects, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both that received sibutramine were followed and similarly showed higher risk for nonfatal MI and nonfatal stroke in these patients. In another cohort study by Harrison-Woolrych et al.,[@b40-ARYA-11-295] the studied cohort experienced significant AEs of hypertension, palpitations, hypotensive events and tachycardia, but with a low risk for cardiac death. Maggioni et al.[@b41-ARYA-11-295] also indicated that only 3.1% of patients treated with sibutramine discontinued their regimen because of some slight complications including drug intolerance, headache, insomnia, nausea, dry mouth, and constipation-, tachycardia-, and hypertension and thus the drug was well tolerated. Gaciong and Placha[@b42-ARYA-11-295] also showed that the patients received sibutramine in single daily doses of 10 and/or 15 mg experienced a tolerable decrease in systolic and diastolic BP and heart rate about 12 weeks of drug use.

***Forth antidepressants group (SARIs)***

In this group, trazodone has been more studied regarding its effects on cardiovascular system. According to the case-control study by Weeke et al.,[@b16-ARYA-11-295] there was no association between the use of SARIs drugs such as trazodone and cardiac-related death. In a case study by Service and Waring[@b43-ARYA-11-295] that described a woman who overdosed by acute ingestion of trazodone, significant QT prolongation and delayed atrioventricular nodal conduction was developed after injecting trazodone. In a retrospective study by Krahn et al.,[@b44-ARYA-11-295] 100 patients who received electroconvulsive therapy with concurrent trazodone, except for orthostatic hypotension that was more observed in patients taking trazodone, no difference was revealed between these patients and the controls and thus using low-dose trazodone does not appear to increase cardiovascular AEs. In an animal study by Boschmans et al.[@b45-ARYA-11-295] on hearts of the rats, trazodone could elicit a significant elevation in coronary flow over the dose range of 2.5-250 µM.

***Fifth antidepressants group (NaSSAs)***

Most studies performed on the cardiovascular effects of NaSSAs have mainly focused their effects on heart rate variability. However, the studies have reached contradictory results. In a meta-analysis study by Kemp et al.,[@b47-ARYA-11-295] mirtazapine had no significant impact on heart rate variability. In a case study by Rajpurohit et al.[@b48-ARYA-11-295] in 2014, subsequent to the first dose of mirtazapine the patient experienced bradycardia and prolonged QRS as well as QTc intervals on ECG pattern. In a study by Terhardt et al.,[@b49-ARYA-11-295]21 moderately depressed patients being treated with mirtazapine that finally experienced increased heart rate and reduced heart rate variability compared with the non-depressed controls. In another trial study by Tulen et al.,[@b46-ARYA-11-295] it was shown that although using mirtazapine had no effect on BP or BP variability, but early after use of this drug, increase in heart rate and decrease in heart rate variability could be observed might be due to the anticholinergic properties of this drug.

Discussion
==========

According to the current review, we recommend to divide antidepressants into three categories based on the severity of cardiovascular adverse consequences including (1) the safest drugs including those drugs with cardio-protective effects on ventricular function as well as cardiac conductive system (SSRIs), (2) neutralized drugs with no evidenced effects on cardiovascular system (SNRIs), and (3) harmful drugs with adverse effects on cardiac function, hemodynamic stability, and heart rate variability (TCAs, SARIs, and NaSSAs). In fact, the cardiovascular effects of the variety of these drugs can referred to the chemical nature of the drug and its effect mechanism. Regarding the harmful cardiovascular effects of TCAs, it has been well demonstrated that blocking the reuptake of norepinephrine and serotonin at nerve terminals is responsible for their effects on cardiac arrhythmias and thus appearing heart conduction impairment. On the other hand, following sodium channel blockade induced by TCAs, prolonged intraventricular conduction in expected. In overdose of TCAs, this conductive prolongation may be also life-threatening because of tending increase in premature ventricular contractions and ventricular tachycardia.[@b31-ARYA-11-295],[@b50-ARYA-11-295]-[@b53-ARYA-11-295] Furthermore, the overdose of this drugs can result in suppressing potassium channels in myocytes leading QT interval prolongation and also appearing the pattern of torsades de pointes.[@b54-ARYA-11-295],[@b55-ARYA-11-295]

In respect to the harmful effects of SARIs such as trazodone, although this group of drugs is structurally different from the TCAs, but because these drugs can selectively blocks the reuptake of serotonin describing their effects on decreasing BP. Furthermore, in some cases, the risk for premature ventricular contractions (PVCs) may be increased following the use of trazodone, however this group is suggested to be very safer than TCAs and thus can be a proper alternative for TCAs.[@b56-ARYA-11-295],[@b57-ARYA-11-295] Along with safety of SARIs, the use of NaSSAs is not recommended in those with cardiovascular abnormalities because of their potential harmful effects on heart rate variability.

Different mechanisms have been identified regarding effects of SSRIs on cardiovascular system. These types of drugs can inhibit the reuptake of serotonin at presynaptic terminals, resulting in increased serotonergic activity in the interneuron space. In this regards, some protective effects of SSRIs may be related to their effects on vasculature, conduction system. One of the main beneficial effects of SSRIs in depressed patients is their effects on platelet activities. It has been shown that the depressed patients have elevated level of platelet adhesion and aggregation leading increased risk for cardiovascular events.[@b56-ARYA-11-295],[@b57-ARYA-11-295] In fact, the use of SSRIs may prevent developing atherosclerotic plaques and also arterial thrombosis.[@b58-ARYA-11-295]-[@b60-ARYA-11-295] Along with their related beneficial effects, the harmful effects of SSRIs on cardiovascular system were only reported in less than 0.0003%[@b61-ARYA-11-295] that can be only observed in drugs overdoses.

Conclusion
==========

In conclusion, it seems that considering the new presented categorization of antidepressants can be clinically helpful to have the best selection for antidepressants to minimizing their cardiovascular harmful effects. However, the completeness of this categorization should be more assessed in further studies.
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###### 

Review of the studies on the effects of antidepressants on cardiovascular system

  Author                                       Country        Study                            Participants                                          End point                                                                               Finding
  -------------------------------------------- -------------- -------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rutledge et al.[@b10-ARYA-11-295]            USA            Retrospective cohort             936 women                                             Depression, dietary habits, and cardiovascular events                                   Mechanisms linking depression to CVD is related to dietary habit
  Thase et al.[@b11-ARYA-11-295]               USA            Clinical trial                   3298 on escitalopram                                  Cardiovascular safety profile of escitalopram                                           escitalopram, like other SSRIs, has a statistically significant effect on heart rate and on ECG values
  Hanash et al.[@b12-ARYA-11-295]              Denmark        Clinical trial                   240 patients with CAD                                 Cardiovascular safety profile of escitalopram                                           One-year escitalopram treatment was safe and well tolerated in patients with recent ACS
  Santangelo et al.[@b13-ARYA-11-295]          Italy          Cohort study                     110 the elderly                                       Sertraline or Citalopram and cardiovascular risk in the elderly                         After 4, 6 and 12 months of treatment, we observed a reduction of the cardiovascular events
  Glassman et al.[@b14-ARYA-11-295]            USA            Clinical trial                   369 patients with depression                          Sertraline treatment of major depression in patients with acute MI or unstable angina   Sertraline is a safe and effective treatment for recurrent depression in patients with recent MI or unstable angina
  Wilens et al.[@b15-ARYA-11-295]              USA            Clinical trial                   187 children and adolescents                          Cardiovascular adverse effects of sertraline in children and adolescents                Cardiovascular safety of sertraline at doses up to 200 mg in children and adolescents
  Weeke et al.[@b16-ARYA-11-295]               Denmark        Case-control                     19,110 patients with out-of-hospital cardiac arrest   Antidepressant use and risk of out-of-hospital cardiac arrest                           An association between cardiac arrest and antidepressant use was documented in both the SSRI and TCA classes of drugs
  Roose et al.[@b17-ARYA-11-295]               USA            Clinical trial                   27 depressed patients with CHD                        Cardiovascular effects of fluoxetine                                                    Fluoxetine treatment was not associated with the cardiovascular effects
  Yeragani et al.[@b18-ARYA-11-295]            USA            Clinical trial                   Depressed cardiac patients                            effects of paroxetine and nortriptyline on long-term heart rate variability measures    nortriptyline has stronger vagolytic effects on cardiac autonomic function compared with paroxetine
  Acharya et al.[@b19-ARYA-11-295]             USA            Retrospective, cross-sectional   664 on antidepressant 472 control                     Antidepressant and cardiovascular events                                                Favor treatment of depression with SSRIs among patients at increased cardiovascular risk
  Pequignot et al.[@b20-ARYA-11-295]           France         Cohort study                     7,308 ones with no history of CAD                     Antidepressants heart disease and stroke events                                         Depressive symptoms are associated with first fatal CHD or stroke events
  Zuidersma et al.[@b21-ARYA-11-295]           Netherland     Clinical trial                   331 depressed MI-patients                             Depression treatment and cardiovascular events                                          Receiving depression treatment increased survival
  Jerrell and McIntyre[@b22-ARYA-11-295]       USA            Retrospective cohort             14,171 children and adolescents                       Cardiovascular and neurological events with antidepressant                              patients were at a significantly higher risk for incident cardiovascular events when exposed to selective serotonin reuptake inhibitors and weight-inducing antidepressants
  Grace et al.[@b23-ARYA-11-295]               USA            Cohort study                     661 ACS inpatients                                    Correlates of antidepressant use in ACS patients                                        Antidepressant users were more likely to be anxious and have more comorbidity, and were less likely to work full-time, whereas number of medications, age, and marital status were not related
  Swenson et al.[@b24-ARYA-11-295]             Canada         Meta-analysis                    6,588 individuals with cardiovascular events          Cardiovascular events in antidepressant trials                                          Did not determine whether SSRIs are associated with a greater or lesser risk of cardiovascular AEs
  Taylor et al.[@b25-ARYA-11-295]              USA            Retrospective cohort             2481 depressed and/or socially isolated patients      Antidepressant medication on morbidity and mortality after MI                           Use of selective serotonin reuptake inhibitors in depressed patients who experience an acute MI might reduce subsequent cardiovascular morbidity and mortality
  Roose et al.[@b26-ARYA-11-295]               USA            Clinical trial                   81 depressed patients with CHD                        paroxetine and nortriptyline in depressed patients with CHD                             Nortriptyline treatment was associated with a significantly higher rate of serious adverse cardiac events compared with paroxetine
  Jeon et al.[@b27-ARYA-11-295]                Korea          Animal study                     4 animal sample                                       Nortriptyline and QT prolongation                                                       Nortriptyline affects the ventricular repolarization process
  Bar et al. [@b28-ARYA-11-295]                Germany        Clinical trial                   52 depressed subjects                                 cardio-respiratory coupling after treatment with nortriptyline                          decreases of non-linear measures of heart rate variability in the nortriptyline group
  Kiev et al.[@b29-ARYA-11-295]                USA            Clinical trial                   58 depressed patients                                 Cardiovascular effects of nortriptyline in depressed outpatients                        Slowing of cardiac conduction and possibly of rate-corrected repolarization
  Thayssen et al.[@b30-ARYA-11-295]            Germany        Clinical trial                   21 elderly depressed patients                         Cardiovascular effect of imipramine and nortriptyline in the elderly                    Neither imipramine nor nortriptyline induced changes in cardiac conduction time measurements or arrhythmias
  Giardina et al.[@b31-ARYA-11-295]            USA            Clinical trial                   Non-depressed cardiac patients                        Imipramine and nortriptyline on left ventricular function and blood pressure            Neither drug significantly changed mean ejection fraction or peak systolic pressure end-systolic volume ratio
  Hamer et al.[@b32-ARYA-11-295]               UK             Cohort study                     14,784 without CAD                                    Antidepressant use and future CVD                                                       The use of TCAs was associated with elevated risk of CVD The use of SSRIs was not associated with CVD Neither class of drug was associated with all-cause mortality risk
  Robinson et al.[@b33-ARYA-11-295]            UK             Clinical trial                   Depressed outpatients                                 Cardiovascular effects of phenelzine and amitriptyline                                  Amitriptyline significantly increased heart rate, while phenelzine produced slowing
  Waslick et al.[@b34-ARYA-11-295]             USA            Clinical trial                   22 subjects                                           Cardiovascular effects of desipramine in children and adults during exercise testing    DMI has only minor effects on the cardiovascular response to exercise, and these effects do not appear age-related
  Ho et al.[@b35-ARYA-11-295]                  Canada         Retrospective cohort             48,876 on venlafaxine 41,238 on sertraline            Adverse cardiac events of venlafaxine                                                   Low to moderate dose venlafaxine is not associated with an increased risk of adverse cardiac events
  Xue et al.[@b36-ARYA-11-295]                 USA            cohort study                     64,000 cases                                          Duloxetine and cardiovascular events                                                    The incidence of cardiovascular events did not differ among duloxetine initiators relative to other antidepressant but was higher than those without depression
  Wernicke et al.[@b37-ARYA-11-295]            USA            Meta-analysis                    8504 depressed subjects                               Cardiovascular safety profile of duloxetine                                             Use of duloxetine does not appear to be associated with significant cardiovascular risks
  Scheen[@b38-ARYA-11-295]                     Belgium        cohort study                     10â€‰742 overweight/obese subjects                    Cardiovascular risk-benefit profile of sibutramine                                      Drug should not be prescribed for overweight/obese patients with a high cardiovascular risk profile
  James et al.[@b39-ARYA-11-295]               UK             cohort study                     10,744 overweight or obese subjects                   Cardiovascular risk-benefit profile of sibutramine                                      Long-term sibutramine treatment had an increased risk of nonfatal MI and nonfatal stroke but not of cardiovascular death
  Harrison-Woolrych et al.[@b40-ARYA-11-295]   New Zealand    cohort study                     15 686 overweight or obese subjects                   Cardiovascular risk-benefit profile of sibutramine                                      Risk of death from a cardiovascular event in this general population of patients prescribed sibutramine was lower than has been reported in other overweight/obese populations
  Maggioni et al.[@b41-ARYA-11-295]            Italy          Cohort study                     10,742 cases with CAD                                 Cardiovascular risk-benefit profile of sibutramine                                      overall mortality rate was low and sibutramine was well tolerated
  Gaciong and Placha[@b42-ARYA-11-295]         Poland         Cohort study                     2225 overweight and obese subjects                    Cardiovascular risk-benefit profile of sibutramine                                      Treatment with sibutramine resulted in clinically significant weight loss during short-term therapy in obese adults
  Service and Waring[@b43-ARYA-11-295]         UK             Case study                       A depressed woman                                     QT prolongation and delayed atrioventricular conduction by ingestion of trazodone       The possibility of cardiotoxic effects after trazodone overdose
  Krahn et al.[@b44-ARYA-11-295]               USA            Retrospective                    100 patients who received ECT                         Cardiovascular complications in patients taking trazodone                               Administering low-dose trazodone for insomnia in conjunction with ECT does not appear to increase cardiovascular complications
  Boschmans et al.[@b45-ARYA-11-295]           South Africa   Animal study                     Heart rats                                            Coronary vascular responses after trazodone                                             Trazodone elicited a marked elevation in coronary flow over the dose range of 2.5-250 آµM
  Tulen et al.[@b46-ARYA-11-295]               Netherlands    Clinical trial                   10 depressed ones                                     Cardiovascular variability due to mirtazapine                                           Increase in heart rate and decrease in heart rate variability

SSRIs: Selective serotonin re-uptake inhibitors; ECG: Electrocardiogram; CAD: Coronary artery disease; ACS: Acute coronary syndrome; MI: Myocardial infarction; CHD: Coronary heart disease; AEs: Adverse events; TCAs: Tricyclic antidepressants; CVD: Cardiovascular disease; ECT: Electroconvulsive therapy; DMI: Desipramine
